Hanson, Julien ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
De Leval, X.
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
Supuran, C.
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Dogné, Jean-Michel ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
DOGNE JM, LEVAL XD X, BENOIT P et al.: Recent advances in antiplatelet agents. Curr. Med. Chem. (2002) 9:577-589.
BENOIT P, DOGNE JM: Platelet ADP receptors and their antagonists. Mini. Rev. Med. Chem. (2003) 3:145-148.
PHILLIPS DR, JENNINGS LK, EDWARDS HH: Identification of membrane proteins mediating the interaction of human platelets. J. Cell. Biol. (1980) 86:77-86.
WAGNER CL, MASCELLI MA, NEBLOCK DS et al.: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:907-914.
FRENETTE PS, WAGNER DD: Adhesion molecules-Part II: blood vessels and blood cells. N. Engl. J. Med. (1996) 335:43-45.
FRENETTE PS, WAGNER DD: Adhesion molecules-Part 1. N. Engl. J. Med. (1996) 334:1526-1529.
COLLER BS, PEERSCHKE EI, SCUDDER LE, SULLIVAN CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. (1983) 72:325-338.
MOSESSON MW, SIEBENLIST KR, MEH DA. The structure and biological features of fibrinogen and fibrin. Ann. NY Acad. Sci. (2001) 936:11-30.
COLLER BS: A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. (1985) 76:101-108.
COLLER BS, SCUDDER LE, BEER J et al.: Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. NY Acad. Sci. (1991) 614:193-213.
CHARO IF, BEKEART LS, PHILLIPS DR: Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J. Biol. Chem. (1987) 262:9935-9938.
ALTIERI DC, EDGINGTON TS: A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J. Immunol. (1988) 141:2656-2660.
NO AUTHORS LISTED: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349:1429-1435.
NO AUTHORS LISTED: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N. Engl. J. Med. (1997) 336:1689-1696.
NO AUTHORS LISTED: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N. Engl. J. Med. (1994) 330:956-961.
TCHENG JE, O'SHEA JC: Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. Expert. Opin. Investig. Drugs. (1999) 8:1893-1905.
SCARBOROUGH RM, ROSE JW, HSU MA et al.: Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus M. barbouri. J. Biol. Chem. (1991) 266:9359-9362.
SCARBOROUGH RM, NAUGHTON MA, TENG W et al.: Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. (1993) 268:1066-1073.
NO AUTHORS LISTED: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. (1998) 339:436-443.
NO AUTHORS LISTED: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet (1997) 349:1422-1428.
HARTMAN GD, EGBERTSON MS, HALCZENKO W et al.: Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. (1992) 35:4640-4642.
NO AUTHORS LISTED: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. N. Engl. J. Med. (1998) 338:1498-1505.
NO AUTHORS LISTED: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N. Engl. J. Med. (1998) 338:1488-1497.
CO MS, YANO S, HSU RK et al.: A humanized antibody specific for the platelet integrin gpIIb/IIIa. J. Immunol. (1994) 152:2968-2976.
KAKU S, KAWASAKI T, HISAMICHI N et al.: Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb. Haemost. (1996) 75:679-684.
SUZUKI K, SAKAI Y, HISAMICHI N et al.: Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur. J. Pharmacol. (1997) 336:169-176.
HARDER S, KIRCHMAIER CM, KRZYWANEK HJ et al.: Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation (1999) 100:1175-1181.
ALIG L, EDENHOFER A, HADVARY P et al.: Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. (1992) 35:4393-4407.
THEROUX P, KOUZ S, ROY L et al.: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian lamifiban study. Circulation (1996) 94:899-905.
NO AUTHORS LISTED: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation (1998) 97:2386-2395.
MOLITERNO DJ: Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B international steering committee. Am. Heart. J. (2000) 139:563-566.
GLOBAL ORGANIZATION NETWORK (PARAGON)-B INVESTIGATORS: Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation (2002) 105:316-321.
WELLER T, ALIG L, BERESINI M et al.: Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. (1996) 39:3139-3147.
REFINO CJ, MODI NB, BULLENS S et al.: Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GPIIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb. Haemost. (1998) 79:169-176.
THE SYMPHONY INVESTIGATORS: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet (2000) 355:337-345.
SECOND SYMPHONY INVESTIGATORS: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation (2001) 103:1727-1733.
O'NEILL WW, SERRUYS P, KNUDTSON M et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N. Engl. J. Med. (2000) 342:1316-1324.
OGAWA T, SUGIDACHI A, NAGANUMA H, ASAI F: Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs. Thromb. Res. (2000) 97:307-315.
ANDERS R, KLEIMAN J, NICHOLSON N, WAZOWICZ B, BURNS D: Xemilofiban/orbofiban: insight into drug development. Cardiovasc. Drug. Rev. (2001) 19:116-132.
CANNON CP, MCCABE CH, WILCOX RG et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation (2000) 102:149-156.
LIU F, CRAFT RM, MORRIS SA, CARROLL RC: Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert. Opin. Investig. Drugs (2000) 9:2673-2687.
TOPOL EJ, EASTON JD, AMARENCO P et al.: Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am. Heart. J. (2000) 139:927-933.
SORELLE R: SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor. Circulation (2001) 103:E9001-E9002.
CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation (2001) 103:201-206.
ADDERLEY SR, FITZGERALD DJ: Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J. Biol. Chem. (2000) 275:5760-5766.
ERHARDT JA, OHLSTEIN EH, TOOMEY JR et al.: Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb. Res. (2001) 103:143-148.
PETER K, SCHWARZ M, YLANNE J et al.: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood (1998) 92:3240-3249.
COX D, SMITH R, QUINN M et al.: Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J. Am. Coll. Cardiol. (2000) 36:1514-1519.
HOLMES MB, SOBEL BE, CANNON CP, SCHNEIDER DJ: Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction. Am. J. Cardiol. (2000) 85:491-493, A410.
MOUSA SA, FORSYTHE M, LORELLI W et al.: Novel non-peptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron. Artery. Dis. (1996) 7:767-774.
XUE CB, WITYAK J, SIELECKI TM et al.: Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists. J. Med. Chem. (1997) 40:2064-2084.
MOUSA SA, KAPIL R, MU DX: Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2535-2541.
PIENIASZEK HJ Jr, SY SK, EBLING W et al.: Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J. Clin. Pharmacol. (2002) 42:738-753.
MOUSA SA, FORSYTHE M, BOZARTH J et al.: XV454, a novel non-peptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet αIIbβ3-binding kinetics to c7E3. J. Cardiovasc. Pharmacol. (1998) 32:736-744.
MOUSA SA, BOZARTH JM, NAIK UP, SLEE A: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br. J. Pharmacol. (2001) 133:331-336.
MULLER TH, WEISENBERGER H, BRICKL R et al.: Profound and sustained inhibition of platelet aggregation by fradafiban, a non-peptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation (1997) 96:1130-1138.
AKKERHUIS KM, NEUHAUS KL, WILCOX RG et al.: Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a Phase II study. Eur. Heart. J. (2000) 21:2042-2055.
HOEKSTRA WJ, BEAVERS MP, ANDRADE-GORDON P et al.: Design and evaluation of non-peptide fibrinogen γ-chain based GPIIb/IIIa antagonists. J. Med. Chem. (1995) 38:1582-1592.
HOEKSTRA WJ, MARYANOFF BE, DAMIANO BP et al.: Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J. Med. Chem. (1999) 42:5254-5265.
DAMIANO BP, MITCHELL JA, GIARDINO E et al.: Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb. Res. (2001) 104:113-126.
VAN HECKEN A, DEPRE M, WYNANTS K et al.: Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug. Metabol. Drug. Interact. (1998) 14:193-205.
MEIBOHM B, NEUGEBAUER R, BUHRING KU, SCHULTE M, KOVAR A: J. Clin. Pharmacol. (1999) 39:978.
HUANG J, REBELLO SS, ROSENBERG LA et al.: Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Eur. J. Pharmacol. (1999) 366:203-213.
REBELLO SS, HUANG J, SHIU WJ et al.: Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. J. Cardiovasc. Pharmacol. (1998) 32:485-494.
REBELLO SS, HUANG J, SAITO K, LUCCHESI BR: In vivo efficacy of SM-20302, a GPIIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler. Thromb. Vasc. Biol. (1998) 18:954-960.
HORISAWA S, KANEKO M, SAKURAMA T: SM-20302, a non-peptide GPIIb/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed hemorrhage model in mice. Thromb. Haemost. (1999) 82:1743-1748.
HORISAWA S, KANEKO M, IKEDA Y, UEKI Y, SAKURAMA T: Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs. Thromb. Res. (1999) 94:227-234.
HORISAWA S, KANEKO M, SAKURAMA T: Protective effects of SM-20302, an orally active GPIIb/IIIa antagonist, in an ADP/epinephrine-induced guinea pig model of transient cerebral ischemia. Thromb. Res. (2001) 101:119-126.
SMALLHEER JM, OLSON RE, WEXLER RR: Antiplatelet therapies. Ann. Rep. Med. Chem. (2000) 35:103-122.
KAWAMURA M, TSUJI N, MORIYA N, TERASHITA Z: Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb. Res. (1997) 86:275-285.
KAWAMURA M, IMURA Y, MORIYA N et al.: Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J. Pharmacol. Exp. Ther. (1996) 277:502-510.
STILZ HU, GUBA W, JABLONKA B et al.: Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. J. Med. Chem. (2001) 44:1158-1176.
OKUMURA K, SHIMAZAKI T, AOKI Y et al.: New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template. J. Med. Chem. (1998) 41:4036-4052.
BANNO H, KAWAZURA H, YUTAKA T et al.: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist. Eur. J. Pharmacol. (1999) 367:275-282.
BADORC A, BORDES MF, DE COINTET P et al.: New orally active non-peptide fibrinogen receptor (GPIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid-4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent. J. Med. Chem. (1997) 40:3393-3401.
HOFFMANN P, BERNAT A, SAVI P, HERBERT JM: Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. J. Pharmacol. Exp. Ther. (1998) 286:670-675.
SAVI P, BADORC A, LALE A et al.: SR 121787, a new orally active fibrinogen receptor antagonist. Thromb. Haemost. (1998) 80:469-476.
BERNAT A, SAVI P, LALE A, HOFFMANN P, HERBERT JM: The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent Factor Xa inhibition without an increase in the bleeding risk in the rabbit. J. Cardiovasc. Pharmacol. (1999) 33:573-579.
HARADA T, KATADA J, TACHIKI A et al.: Development of the new potent non-peptide GPIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique. Bioorg. Med. Chem. Lett. (1997) 7:209-212.
HAYASHI Y, KATADA J, HARADA T et al.: GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure. J. Med. Chem. (1998) 41:2345-2360.
OLSON RE, SIELECKI TM, WITYAK J et al.: Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J. Med. Chem. (1999) 42:1178-1192.
MOUSA SA, OLSON RE, BOZARTH JM et al.: Oral antiplatelet efficacy and specificity of a novel non-peptide platelet GPIIb/IIIa receptor antagonist, DMP 802. J. Cardiovasc. Pharmacol. (1998) 32:169-176.
SIELECKI TM, LIU J, MOUSA SA et al.: Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2201-2204.
SMYTH MS, ROSE J, MEHROTRA MM et al.: Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes. Bioorg. Med. Chem. Lett. (2001) 11:1289-1292.
PANDEY A, SEROOGY J, VOLKOTS D et al.: Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes. Bioorg. Med. Chem. Lett. (2001) 11:1293-1296.
MEHROTRA MM, HEATH JA, ROSE JW et al.: Spirocyclic non-peptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes. Bioorg. Med. Chem. Lett. (2002) 12:1103-1107.
LIVERTON NJ, ARMSTRONG DJ, CLAREMON DA et al.: Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett. (1998) 8:483-486.
ROBARGE KD, DINA MS, SOMERS TC et al.: Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorg. Med. Chem. (1998) 6:2345-2381.
BLACKBURN BK, LEE A, BAIER M et al.: From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. J. Med. Chem. (1997) 40:717-729.
ADDICKS E, MAZITSCHEK R, GIANNIS A: Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues. Chembiochem. (2002) 3:1078-1088.
EGBERTSON MS, COOK JJ, BEDNAR B et al.: Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J. Med. Chem. (1999) 42:2409-2421.
FISHER MJ, ARFSTAN AE, GIESE U et al.: Fused bicyclic Gly-Asp β-turn mimics with specific affinity for GPIIb-IIIa. J. Med. Chem. (1999) 42:4875-4889.
FISHER MJ, GIESE U, HARMS CS et al.: Fused bicyclic Gly-Asp β-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere. Bioorg. Med. Chem. Lett. (2000) 10:385-389.
SUGIHARA H, FUKUSHI H, MIYAWAKI T et al.: Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J. Med. Chem. (1998) 41:489-502.
KITAMURA S, FUKUSHI H, MIYAWAKI T et al.: Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives. J. Med. Chem. (2001) 44:2438-2450.
FELDING-HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr. Opin. Cell Biol. (1993) 5:864-868.
COLLER BS, CHERESH DA, ASCH E, SELIGSOHN U: Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood (1991) 77:75-83.
SRIVATSA SS, FITZPATRICK LA, TSAO PW et al.: Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointima formation. Cardiovasc. Res. (1997) 36:408-428.
BENNETT JS, CHAN C, VILAIRE G, MOUSA SA, DEGRADO WF: Agonist-activated αvβ3 on platelets and lymphocytes binds to the matrix protein osteopontin. J. Biol. Chem. (1997) 272:8137-8140.
REVERTER JC, BEGUIN S, KESSELS H et al.: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J. Clin. Invest. (1996) 98:863-874.
STOUFFER GA, HU Z, SAJID M et al.: β3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation (1998) 97:907-915.
HOSHIGA M, ALPERS CE, SMITH LL, GIACHELLI CM, SCHWARTZ SM: αvβ3 integrin expression in normal and atherosclerotic artery. Circ. Res. (1995) 77:1129-1135.
SLEPIAN MJ, MASSIA SP, DEHDASHTI B, FRITZ A, WHITESELL L: β3-integrins rather than β1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation (1998) 97:1818-1827.
BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular integrin αvβ3 for angiogenesis. Science (1994) 264:569-571.
BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994 ) 79:1157-1164.
BROOKS PC, STROMBLAD S, KLEMKE R et al.: Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815-1822.
VARNER JA, CHERESH DA: Integrins and cancer. Curr. Opin. Cell Biol. (1996) 8:724-730.
ALI FE, BENNETT DB, CALVO RR et al.: Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J. Med. Chem. (1994) 37:769-780.
WONG A, HWANG SM, MCDEVITT P et al.: Studies on αvβ3/ligand interactions using a [3H]SK&F-107260 binding assay. Mol. Pharmacol. (1996)